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ABSTRACT

Ornithine decarboxylase (ODC) is the first and rate-limiting
enzyme in the synthesis of polyamines, which play a regulatory role
in nucleic acid and protein synthesis.

The enzyme may be involved in

normal and abnormal growth of the myocardium, in the relationship
between mechanical stress and protein synthesis, and in the
development of left ventricular hypertrophy (LVH).

Results from this

and other laboratories suggest that experimental diabetes has a more
profound effect on mechanical function and cellular growth of
hypertrophic heart muscle than it does on nonhypertrophic tissue.
Diabetes is associated with reduced serum levels of both insulin and
thyroid hormone.

Both of these hormones are demonstrated regulators

of ODC activity.

Despite this, relatively little is known about the

effects of diabetes on cardiac ODC activity and polyamine synthesis
in the presence or absence of LVH.

Therefore, we have hypothesized

that: 1) ODC activity of hypertrophic left ventricle in spontaneously
hypertensive rat (SHR) is higher than that of nonhypertrophic left
ventricle in the normotensive rat strains, Wistar Kyoto (WKY) and
Sprague Dawley (SD); 2) Untreated diabetes will reduce left
ventricular ODC activity of SHR and of nonhypertensive rats, but its
effects on the former will be greater in magnitude; 3) The effects of
diabetes on left ventricular ODC activity, of either SHR or
normotensive rats, will be preventable with insulin treatment, and at
least partially preventable by thyroid hormone treatment, in vivo.
Diabetes was induced in SHR and WKY by Streptozotocin (STZ) at 15
weeks of age.

Subgroups were treated with insulin or

ii

triiodothyronine (T ).
3

After 8 weeks of treatment, left and right

ventricles were assayed for ODC activity, by measuring the rate of
evolution of

14

co 2 from (1- 14 c) L-ornithine.

The results show that

left ventricular ODC activity of nondiabetic SHR was not
significantly different from that of either the WKY or SD
normotensive rats. Streptozotocin-induced diabetes reduced left
ventricular ODC activity to about the same extent in the hypertrophic
SHR and in the nonhypertrophic WKY, depressing V
without affecting
max
the apparent K of the enzyme in both strains.
m

However, experimental

diabetes had no effect on right ventricular ODC activity in either
the SHR or WKY strains.

Both insulin and T treatment were partially
3

effective in preventing the reductions in ODC activity caused by
diabetes.

The results show that the depression in ODC activity

caused by untreated diabetes

1) Is selective for the left

ventricle perhaps because of its relatively greater workload;

2) Is

not selective for the hypertrophic ventricle in the SHR strain; and
3) May be related, in part, to the effects of the hypothyroidism
which attends diabetes. These results do not support a causal
relationship between left ventricular ODC activity and the
maintenance of hypertrophy, nor do they support a predisposition of
left ventricular hypertrophy to influences of diabetes on ODC
activity (Hypotheses 1 and 2).

The results do support a

participation of attendant hypothyroidism in the effects of diabetes
on left ventricular ODC activity (Hypothesis 3).

iii
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MYOCARDIAL ORNITHINE DECARBOXYLASE OF HYPERTENSIVE
AND DIABETIC RATS:

EFFECTS OF INSULIN AND

TRIIODOTHYRONINE TREATMENT

ABSTRACT

Ornithine decarboxylase (ODC) is the first and rate-limiting
enzyme in the synthesis of polyamines, which play a regulatory role
in nucleic acid and protein synthesis.

The enzyme may be involved in

normal and abnormal growth of the myocardium, in the relationship
between mechanical stress and protein synthesis, and in the
development of left ventricular hypertrophy (LVH).

Results from this

and other laboratories suggest that experimental diabetes has a more
profound effect on mechanical function and cellular growth of
hypertrophic heart muscle than it does on nonhypertrophic tissue.
Diabetes is associated with reduced serum levels of both insulin and
thyroid hormone.

Both of these hormones are demonstrated regulators

of ODC activity.

Despite this, relatively little is known about the

effects of diabetes on cardiac ODC activity and polyamine synthesis
in the presence or absence of LVH.

Therefore, we have investigated

the possible role of ODC in LVH in the spontaneously hypertensive rat
(SHR) and in the non-hypertensive Wistar Kyoto (WKY) and Sprague
Dawley (SD) strains.

We also examined the effects of diabetes on

cardiac ODC activity in the presence and absence of LVH.

The results

show that left ventricular ODC activity of nondiabetic SHR was not
significantly different from that of either the WKY or SD
normotensive rats.

Streptozotocin-induced diabetes reduced left

ventricular ODC activity to about the same extent in the hypertrophic
SHR and in the nonhypertrophic WKY, depressing V
without affecting
max
the apparent K of the enzyme in both strains.
m

However, experimental

diabetes had no effect on right ventricular ODC activity in either

2

the SHR or WK.Y strains.

Both insulin and triiodothyronine (T )
3

treatment were partially effective in preventing the reductions in

ODC activity caused by diabetes.

The results show that the

depression in ODC activity caused by untreated diabetes

1) Is

selective for the left ventricle perhaps because of its relatively
greater workload;

2) Is not selective for the hypertrophic ventricle

in the SHR strain; and

3) May be related, in part, to the effects of

the hypothyroidism which attends diabetes.

3

INTRODUCTION

The polyamines - putrescine, spermidine, and spermine - play an
important regulatory role in nucleic acid and protein synthesis and
cellular growth (23, 47, 72, 73).

The initial step in their

formation is catalyzed by ornithine decarboxylase (ODC, EC 4.1.1.17),
which converts ornithine to putrescine, and appears to be the
rate-limiting enzyme for polyamine synthesis

(44, 61).

one

is

unique in that its half-life is approximately 10-20 minutes, the
shortest of any known mammalian enzyme (40, 64).

one

The activities of

and putrescine fluctuate rapidly and specifically in response to

a variety of hormonal and metabolic factors that alter cell growth
(73).

one

Thus

is markedly increased in tissues in which growth is

accelerated, and its activity is usually low when the rate of growth
is slow (11).
Cardiac hypertrophy is an early adaptive response to increased
functional demand on the heart, such as pressure or volume overload
(52, 80).

The message by which increased mechanical stress is

translated into increased protein synthesis and hypertrophy is not
clear (60, 84).

As a growth-regulating enzyme, ODC is a plausible

point of control in the hypertrophy process.

However, the extent to

which ODC may contribute to the development and maintenance of
myocardial hypertrophy is not well defined.

The activity of ODC is

normally higher in the left ventricle than in the right, which seems
to be a reflection of the relatively greater work required of this
chamber (6).

A rise in ODC activity is a well documented biochemical

4

event in the development of hypertrophy in a variety of tissues (3,
21).

Previous studies have shown an increase in polyamine

concentration and cardiac one activity in the hypertrophic response
to aortic constriction (17, 40), catecholamines (3, 4, 9, 22, 30),
thyroid hormone (12, 13, 45, 46, 54) and hypoxia (32, 55).

The fact

that stimulation of myocardial one activity precedes the development
of hypertrophy suggests that increased polyamine synthesis may be an
important regulatory component of cardiac hypertrophy (39, 40, 60,
62).

In fact, a temporal relationship has been described by

Calderera et al. (10) between an increase in polyamine concentration
which precedes an increase in RNA synthesis during the early stages
of exercise-induced cardiac hypertrophy.

In addition to these acute

studies, the results of Ruskoaho et al. (60) show that the onset of
left ventricular hypertrophy over time in the spontaneously
hypertensive rat (SHR) model of hypertension is associated with
elevated left ventricular ODe activity.

Boucek et al. (7) have shown

that changes in tension development alone in isolated rabbit
papillary muscles can stimulate one activity.
It is well known that diabetes diminishes protein and RNA
synthesis (16, 43) and accelerates protein degradation (81) in a
variety of tissues, including cardiac muscle.

Previous studies in

this and other laboratories have also shown that diabetes reduces
heart size, and in the SHR model of hypertension may also reverse
left ventricular hypertrophy (15, 58, 70). Despite this, relatively
little is known about the effects of diabetes on cardiac ODC activity
and polyamine synthesis in the presence or absence of hypertension.
Indeed, the influence of diabetes on one activity in any tissue is

5

not well characterized. Levine et al. (36) and Brosnan et al. (8) and
others (25, 59) have reported an increase in ODC activity in liver
and kidney of diabetic normotensive rats.

However, Sochor et al.

(69) and Conover et al. (14) both reported profound decreases in ODC
activity in liver and heart of diabetic rats which could be prevented
with insulin treatment.

The effect of diabetes on myocardial ODC

activity has not been investigated in any model of cardiac
hypertrophy.
An attendant hypothyroidism, or "low thyroid state" (53), is

often associated with human and experimental diabetes.
Hypothyroidism alone decreases myocardial ODC activity (13), and
thyroid hormone is an established regulator of myocardial ODC
activity (12, 13, 54).

Thus, studies of the effects of experimental

diabetes on ODC activity should be designed to take into account the
possible influence of attendant hypothyroidism.
The central hypotheses of the proposed study can be stated as
follows:

1) ODC activity of hypertrophic left ventricle in SHR, at a

given age, is higher than that of nonhypertrophic left ventricle in
normotensive rat strains; 2) Untreated diabetes of moderate severity
and eight weeks duration will reduce left ventricular ODC activity of
SHR and of nonhypertensive rats, but its effect on the former will be
greater in magnitude; 3) Effects of diabetes on left ventricular ODC
activity, of either SHR or normotensive rats, will be preventable
with insulin therapy, and at least partially preventable by thyroid
hormone treatment, in vivo.

Secondary aims of the study include

comparisons of left and right ventricular ODC activities of

6

nondiabetic SHR and normotensive rats, and analysis of the kinetics
of ODC obtained from nondiabetic and diabetic rat left ventricle.

7

MATERIALS AND METHODS

Experimental Groups and Treatments.

Male Spontaneously Hypertensive

rats (SHR) and age-matched normotensive control Wistar Kyoto (WKY)
and Sprague Dawley (SD) rats were obtained from Charles River
Breeding Laboratories (Wilmington, MA.).

The animals were housed in

temperature-controlled animal rooms (22°C) with a 12-hr light-dark
cycle (8:00 a.m. to 8:00 p.m.).

They were kept in group cages by

strain and maintained on standard rat chow (Agway Inc., Syracuse,
N.Y.) and tap water ad libitum.

At 15 weeks of age, animals were

matched according to body weight (BW) and blood pressure (SAP) within ·
strains and divided into either diabetic or nondiabetic groups.
Diabetes was induced in the SHR and WKY rat strains via a single tail
vein injection, under light ether anesthesia, of Streptozotocin (STZ,
Sigma Chemical Co., St. Louis, MO.).

The dose of STZ for each strain

was adjusted in order to induce similar degrees of diabetes as
assessed by serum glucose concentrations.

Based on preliminary

results, the doses used in this study for SHR and WKY strains were 45
mg STZ/kg BW and 50 mg STZ/kg BW respectively.

The ·sTZ was dissolved

in citrate buffer (0.1 Mat pH 4.5) just prior to use.

The

nondiabetic animals were also anesthetized and were injected with a
similar volume of citrate buffer.

The duration of either untreated

or treated diabetes was eight weeks and the extent of diabetes was
monitored weekly by urinary glucose measurements (Diastix (R)) and
verified by serum glucose and insulin levels at time of sacrifice.

8

A series of three studies, consisting of separate treatment
groups, were carried out as follows (see Table 4):

1) A preliminary

study of the effects of diabetes on left ventricular ODC activities
in the SHR and WKY rats;

2) The effects of insulin and

triiodothyronine (T ) treatment of diabetic SHR;
3
insulin and T treatment of diabetic WKY.
3

3) The effects of

In addition, kinetic

analyses were performed in Study 3 as described below.

The animals

were divided into experimental and control groups as follows.

The

nondiabetic animals from both SHR and WKY consisted of untreated
controls and those treated with daily administration of 3,5,3'triiodothyronine sodium (T ).
3

Those animals treated with STZ were

subdivided into diabetic and insulin- and T -subgroups.
3

Daily

injections of T (lOug/kg BW, Sigma Chemical Co., St. Louis, MO.)
3
(74) and Protamine Zinc Insulin (I; 10 U/kg BW, Eli Lilly,
Indianapolis, IN.) (75) were administered subcutaneously.
of T

3

This dose

was selected in previous studies in this laboratory according

to its ability to prevent diabetes- induced bradycardia and to
restore low serum thyroid hormone levels of diabetic rats to normal
(15).
In vivo measurements.

Systolic arterial pressure (SAP), heart rate

(HR) and body weight (BW) were taken just prior to tail vein
injections, and then four and eight weeks after STZ injection.

A

standard tail-cuff sphygmomanometer within a temperature controlled
chamber (34°C) was used to measure SAP and HR, after the animals were
prewarmed for 20 minutes (51).

The SAP reported for each rat is the

mean of at least six consecutive measurements.

All measurements were

recorded prior to the daily injections of T or insulin.
3
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Serum assays.

After eight weeks of diabetes (at approximately 23

weeks of age), the animals were sacrificed by decapitation and their
serum collected and stored at -20°C.

Treated animals were always

sacrificed 15-20 hours after their last daily injection.

Serum

titers of glucose were determined by the glucose oxidase assay
(Sigma) and used to evaluate the degree of diabetes.

Animals were

classified retrospectively as diabetic if serum glucose values
exceeded 300 mg/dL.

Radioimmunoassays were used to determine serum

insulin (Micromedic Systems Inc., Horsham, PA.) and total T

3

and

total thyroxine (T ) concentrations (Cambridge Medical Diagnostics,
4
Billerica, MA.).

Rat insulin was generously supplied by Dr . R.

Chance (Eli Lilly) and was used as the standard for the insulin
assays.
Enzyme assays.

The heart was quickly excised, rinsed in ice cold 25

mM HEPES buffer, pH 7.2
(N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid, Research
Organics, Cleveland, OH.), and blotted dry.

The left ventricle with

septum was carefully isolated from the right ventricle and each
weighed separately.

The left ventricle was diced and a 5% homogenate

prepared in hypotonic 25mM HEPES at pH 7.2, using a Bio-Homogenizer
(Biospec Products, Bartlesville, OK.) and centrifuged at 36,000g for
20 minutes.

Triplicate aliquots of the supernatant fluid were used

as the source of the enzyme.

Right ventricles were quickly frozen in
0

liquid nitrogen, stored at -80 C and assayed later.
The activity of ODC was determined by a modification of the
procedure of Russell and Synder (61).
of evolution of

14

co

2

from (1-

14

The assay is based on the rate

c) L-ornithine (Amersham Corp.,

10

Arlington Heights, IL.).

The supernatant fluid was added to the

reaction mixture in a 7 mL glass vial sealed with a rubber stopper
through which was suspended a plastic center well (Kontes Glassware,
Vineland, NJ.) containing 0.35 mL of lM KOH and a small piece of
filter paper.

The assay mixture contained the following at the

designated reaction concentrations in a final volume of 0.5 mL (all
reagents from Sigma):

dithiothreitol, 0.5 mM; pyridoxal phosphate,

0.05 mM; sodium bicarbonate, 3.0 mM; (1-

14

c) L-ornithine, 25 uM,200

uM, or 400 uM (0.1 uCi; approximately 16,000, 2000, or 1000
cpm/nmol); and enzyme preparation, 0.3 mL, equally approximately one
mg of protein.

(Values for left ventricular ODC activity at 200 µM

and 400 uM substrate concentration are in Appendix).
studies (1-

14

In the kinetic

c) L-ornithine was isotopically diluted with unlabelled

L-ornithine to achieve the desired concentrations (6.25 to 300 uM;
approximately 64,000 to 1,350 cpm/nmol).

After diluting the (1-

14

c)

L- ornithine, the open vial was gently stirred at room temperature in
a fume hood for one to two hours in order to release free

14

co 2

and

Assay blanks contained 0.3 mL of 25 mM

minimize background (78).

HEPES in place of cardiac enzyme supernatant and normally averaged SO
cpm/tube/hr.

The lowest signal-to-noise ratio was usually in the

range of 300 to 500 cpm above background for 25 uM ornithine and 150
to 200 cpm for 200 uM ornithine.
The reaction was allowed to proceed for one hour at 37°C and was
terminated by the injection of 0.3 mL of 3.0 M citric acid through
the rubber stopper.
(1-

14

The

14

co 2

generated from the decarboxylation of

c) L-ornithine was distilled into the center well during a

second incubation of one hour.

Approximately 96% of the generated

11

14

co 2

was recovered in one hour (see Appendix).

The center wells

were transferred to scintillation vials for quantification of
radioactivity (counting efficiency - 85%).
verified that the rate of

14

co 2

generation was linear with time and

enzyme concentration (see Appendix).
pmol of

14

co 2

Preliminary experiments

Activity of ODC is expressed as

generated/hr/mg protein in the cell-free supernatant

fluid after determination of protein content by the Lowry method
(37).

Statistical analysis.

The effects of diabetes and the hormone

treatments were evaluated by one- or two-factor analysis of variance
(ANOVA) with repeated measures when appropriate, and the Student
Newman-Keuls test (Statistical Analysis Systems, Cary, NC.) for
multiple comparisons.

Straight lines for kinetic analysis were

determined by linear regression.
was considered sufficient.

A level of significance of p < 0.05

Lower probabilities were not reported.

12

RESULTS

Serum assays.

The effects of STZ-induced diabetes of 8 weeks

duration on measurements of serum glucose, insulin, T and T of SHR
3
4
and WKY rats are swmnarized in Table 1.

Injection of STZ increased

serum glucose, and reduced serum insulin of SHR and WKY rats to the
same extent.

By these criteria, the degree of diabetes was

equivalent in both strains.

The diabetic animals of both strains

were also characterized by depressed serum T and T levels.
4
3

The

magnitude of attendant hypothyroidism was about the same in the two
diabetic groups, but the

T levels of nondiabetic SHR were
3

significantly higher than those of the nondiabetic WKY.
Treatment with T had no effect on serum glucose or insulin
3
levels of any of the experimental groups (Table 1).

Treatment of

diabetic SHR with T restored the depressed serum T levels to
3
3
normal, and also aggravated the decline in serum T , probably by
4
inhibiting TSH production by the pituitary and T secretion from the
4
thyroid gland.

T treatment of nondiabetic SHR had the same
3

depressing effect on T levels, but had no effect on the other serum
4
measurements.

However, the same dose of T , when administered to
3

either nondiabetic or diabetic WKY, significantly increased serum T
3
levels as well as exacerbating the decline in serum T levels.
4
Insulin treatment of diabetic SHR did not correct the
hyperglycemia although it caused a pronounced increase in serum
immunoreactive insulin activity (Table 1).
restore serum T

3

and T levels to normal.
4
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Insulin treatment did not
In contrast, treatment of

diabetic WKY with the same dose of insulin effectively reversed the
hyperglycemia and depressed serum insulin levels, and corrected the
reductions in serum T and T levels.
3
4
Arterial Pressure and Heart Rate In Vivo.

Nondiabetic SHR were

hyper-tensive and tachycardic compared to nondiabetic WKY and SD rats
at both Week 0 and Week 8 (Table 2).

Diabetic SHR were characterized

by depressed SAP and HR after 8 weeks, confirming previous results
(58).

Diabetes had no significant effect on either SAP or HR in the

WKY strain.

Treatment of diabetic SHR with either insulin or T was
3

sufficient to prevent the decrease in both SAP and HR.

Treatment of

nondiabetic SHR with T had no effect on either SAP or HR, but
3
administration of the same dose of T to diabetic and nondiabetic WKY
3
rats did cause significant elevations in both SAP and HR.
Body and Heart Weights.

Left ventricles of SHR were hypertrophic,

both relatively (LVW/BW) and absolutely (LVW/RVW) compared to left
ventricles of the nonhypertensive WKY and SD rats (Table 3).
Diabetes reduced BW, left ventricular weight (LVW), and right
ventricular weight (RVW) of SHR, but did not have a significant
effect on indices of left ventricular hypertrophy .

Diabetes reduced

BW in WKY rats but had no effect on left or right ventricular
weights.

The effects of diabetes on heart weights (LV and RV) were

more pronounced in the SHR than they were in the WKY strain.
Insulin treatment of diabetic SHR either partially or fully
restored BW, LVW, and RVW, but had no effect on LVW/BW or LVW/RVW
(Table 3).
rats.

Insulin treatment effectively restored BW of diabetic WKY

Treatment of diabetic SHR with T caused a slightly greater
3

14

decline in BW and an increase in LVW, leading to a restoration of
LVW/BW.

Treatment of nondiabetic SHR with T increased RVW
3

significantly, and increased LVW/BW. Treatment of nondiabetic and
diabetic WKY with T induced a relative left ventricular hypertrophy
3
(LVW/BW), due apparently to a reduction in body weight.
Ornithine Decarboxylase Activity.

Left ventricular Ornithine

Decarboxylase (ODC) activity in 23 week old nondiabetic SHR was not
significantly different from that of either the WKY or the more
outbred SD rat strain (Table 4, Study 3), confirming previous results
(60).

Diabetes reduced left ventricular (LV) ODC activity in both

SHR and WKY to about the same extent (Table 4, Studies 1, 2, and 3).
Insulin treatment prevented the decline in LV ODC activity in the WKY
(Study 3), but not in the SHR group (Study 2).

Treatment with T was
3

partially effective in preventing the decline in LV ODC activity in
both the SHR and WKY strains (Studies 2 and 3).

The results of Table

4, obtained at a substrate concentration of 25 uM, were confirmed at
a saturating concentration of 200 or 400 uM ornithine (see Table 6,
Appendix).

Right ventricular ODC activity was not significantly

affected either by diabetes or by any treatment (see Table 7,
Appendix).

The activity of the crude enzyme preparation seemed to

display Michaelis-Menten kinetics in both the nondiabetic and
diabetic state (Figure 1). The inset in Figure 1 depicts the
Lineweaver-Burk plots for nondiabetic and diabetic SHR. It
demonstrates that diabetes caused a decrease in V
, but had no
max
effect on the apparent K for ornithine, in the SHR strain.
m

similar pattern was evident in the WKY strain (Table 5).
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A

TABLE I.

Serum glucose, insulin, triiodothyronine and thyroxine levels of
nondiabetic, diabetic and treated SHR, hKY and SD.

Strain
Group

11

Glucose
(r.ig/dl)

Insulin
(µU/r.il)

T

T,
(pg/dl)

(ngfdl)

SHR
Nondiabetic
Diabetic
Diabetic + T

3

Diabetic + I
Nondiabetic + T

3

12

131

±

164>

83

± 22

8

633

+ 55'"

20

±

10*

6

666

± 77"'

31

±

14*

9

676 + 42*

193

6

12

170 + 23

Diabetic

11

636

+ 60;':

3

Di.;l:octic +

·~6

176

117

± 78

23

±

6*

.;1

±

29*

± 1.8

> ;oo ....

187 +

2)

161,

± 57

160 +

l.~

l·~

± 37

+ 12*

125 + 45

0. I 7
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TABLE 2.

Systolic arterial pressure and heart rates of nondiabetic, diabetic
.;nd treated SHJ<, \.'KY .;nd SD.

Strain
Group

Diabetic
3

Diabetic + I
::-londiabetic + t

3

Week 0

~eek

198 ±: 13.P

399 + 32.P

8

179 + 2!.

14·~

±:

389 + 26

6

185

± 16

18!. + 26

9

175

± 16

191

6

174

±: 18

203 ±: 1-"

:\ondiabetic

12

127 + 11

Di2betic

11

1211

Diabetic + r

3

DLil:etic +
:-lcr.diabetic + T

±:

11

127 +

9

128 + 18

7

3

8

175 + 16.P

12

Nondiabetic

Diabetic + t

HJ< (beats/min)
\,'eek 0
\.'eek 8

SAP (r.ll:lHg)
n

12!1 +

±

15*

13

374 ±: 27

468 + 37

379 ±: 25
402

±:

20

1-'<3

±:

11

29!.

±:

19<1>

:oo ± 22r:>

I 2'l

±:

9

310

±

12

270

± 18

307 .:!: 17
lid .:!: l

f)

9

301 ±: 12
~21

+ 20

S 1l

111 +

l.'.'l .:!: 1-'1
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TABLE 3.

Body and heart \.:eights of nondiabetic, diabetic and treated SHR, \..'KY
and SD.

Strain
Group

11

ew

LV

RV

LV/RV

( g)

( ng)

(r.ig)

(ng/mg)

LV/B\./
(ng/g)

SHR

12

3~2

± 31¢>

980 + 92<!>

202

± 27

!-4. 9.~

Diabetic

s

191

± 23"'

510

± 69*

133

± 26"'

Diabetic + TJ

6

179

± 24;':

571

± 91 "'

11,3

!"

Diabetic + I

9

299

± 23

i56

± 65'""'

191

6

331

± 30

± 33"'
± 27
± 4 ;';

Nondiabetic

12

1,03

± 25<!>

Diabetic

II

J.',O

:!:

Nondiabetic

~ondiabetic

+ T1

1013 +118

21'3

.'~

~·:

± 0. 77<1>

2.87

± 0.14¢

3.95 + 0.91

2.68

± 0. 17

11

± 0. 76

3. 18

± 0. 18"'"'

1,. 0 l

± 0.56

2 .5 3

± 0.13

!, • 11

± 0.91

3 .08

± 0. 25*"'
± 0. 10<1>

\..'KY

2.',;';

903 + 61¢

229

± .~ 1

1,. 01.

± 0. 70

2. 21.

7'J6 .!:. 83
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± .',()

3. i 5

± 0.59

2.36 + 0. 15

Diabetic + Tl

30.'i + 1,Qo';

890

± 35

233

± :n
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2. 97 .!:. 0 . .'~ 7 ;·,~·:
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!,JI
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:!: 115
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TABLE 4.

Left Ventricular ODC activity in
SHR, \..1\Y and SD rats.

Strain
Group

non~iabetic,

diabetic and treated

I.EFT \"E\'HICULAR ODC ACTIVITY
(pmol
co 2 /hr/mg protein)
n

STUDY 2

n

STUDY 3

n

123

3

JOO + 16

8

66 + 13

'·

35

2

56 + 22"''

5

24 + 10"''

3

71 + 27'""

6

,,3 + 14'°'

<]

97 + 18

6

8

61 + 13

·•

•.
~··.f

·I

STUDY 1

SHR
~ondiabetic

Diabetic

Diabetic + I
~ondiabetic

+

r

3

t\'ondiabetic

99

2

87 + 23

Diabetic

20

...

I.')

Diabetic + T

i:ibet ic + T

+ 1 J"'

2

~

J.',~

52

~

20

.'~

3

Diabetic +
~fond

+ 20""

'

. ·,

; () :+: .'S

3

SD
\'cnJi.ibnr. ic

li6 +

l.'1
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trP. ::. t ::H!lltS.
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(wilhi11 s :r.li11; p < 0.05).
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Figure 1.

Ornithine decarboxylase (ODC) activity of nondiabetic and
diabetic SHR left ventricle, at various substrate
concentrations. Inset: Lineweaver-Burk Plot of left
ventricular ODC activity.
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TABLE 5.

Left ventricul.:;r ODC kinetics in nondiabetic and
diabetic SHR, \;).:y and SD rats.

Strain
Gr cup

Jl

Kn
( µM)

(pmol

1

, Vmax

"co 2 /hr/mg

prot.)

SHR
Nondiabetic

1,

26.3

± 9.9

111. 4

± 21.5

Diabetic

J

23.7

± 5.7

51. 2

± 8. 8'

~ondiabetic

,,

26.0

± 9.6

118. 5

±

12. 7

Diabetic

.',

31. 6

±

61. 0

±

13. 2·:,

0
'

1-'KY

7. l

Va.lues are neans ± SE!1, cbta.ined 8 weeks after initiation of diabetes or
trcatr:ients.
'' Signific~ntly different from the nondiabetic group ("1ithin strain; p <0.05).
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DISCUSSION

The first two related hypotheses of the proposed study, that ODC
activity of nondiabetic, hypertrophic spontaneously hypertensive rat
(SHR) left ventricle would be higher than that of the nonhypertensive
rat strains, and that diabetes would exert a selective effect in the
SHR, were not supported by the results.

The rationale for the

hypotheses was derived, in part, from the assumption that ODC
activity could be

associ~ted

with both the development and

maintenance of left ventricular hypertrophy in a variety of
experimental models (3, 4, 10, 13, 17, 30, 40, 54, 60).

SHR exhibit

a relatively slow progressive increase in arterial pressure and left
ventricular mass (52, 80, 84), characterized by a thickening of the
left ventricular wall (left ventricular hypertrophy).

Thus, this

model of hypertrophy is similar to the cardiac alterations seen in
essential (idiopathic) hypertension in humans (77, 80).
Diabetes affects a number of variables which conceivably might
influence the course of hypertrophy development in the left
ventricle.

One proposed etiologic factor in the development of

hypertensive hypertrophy in the SHR model is an increase in either
the activity of, or the myocardial responsiveness to, sympathoadrenal
influences (1, 83).

Catecholamines, the mediators of sympathetic

activation, stimulate myocardial ODC activity and induce left
ventricular hypertrophy (4, 9, 22, 30, 76).

One consequence of

untreated diabetes is interference with sympathetic activation of
cardiac muscle, characterized in part bY. a reduction in the density
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of beta adrenoceptors (16, 24, 79).

Another proposed stimulus of

cardiac ODC activity is physical stress on the ventricular wall (7).
Left ventricular hypertrophy results in part from elevated wall
stress secondary to abnormally increased total vascular resistance
(80).

Previous studies from this laboratory and others have shown

that diabetes reduces arterial pressure of SHR (15, 58, 70), and thus
would likely relieve the pressure load on the left ventricle.

The

depressor effect of diabetes in SHR was confirmed in the present
study (Table 2).

The earlier studies also showed that diabetes

caused a relatively more pronounced reduction in whole heart and left
ventricular

m~ss

in SHR than it did in the WKY strain, associated

with an inconsistent reversal of left ventricular hypertrophy (15,
58).
The only available study of ODC activity in nondiabetic SHR
myocardium was reported by Ruskoaho et al (60).

They observed that

left ventricular (LV) ODC activity was elevated in the SHR, relative
to that of the WKY, only in young animals during the development of
left ventricular hypertrophy.

However, after left ventricular

hypertrophy was established, beginning at about 20 weeks of age, the
ODC activities of SHR and nonhypertensive WKY rat left ventricle were
not different.

The results of this study (Table 4), confirm those of

Ruskoaho et al. (60).

At 23 weeks of age, the activity of LV ODC in

SHR was similar to that of the WKY and the more outbred SD rat.

The

results also show that the effect of diabetes on ODC activity was
approximately equal in magnitude in the hypertrophic SHR and
nonhypertrophic WKY left ventricle (Table 4).

Thus, hypertrophy did

not seem to predispose the left ventricle to the influences of
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diabetes on LV ODC activity.

These results are not consistent with a

role of increased ODC activity in the maintenance of left ventricular
hypertrophy in the SHR.
Although diabetes did not exert a selective effect on
hypertrophic myocardial ODC activity, it did exhibit a preferential
action on the left ventricle versus the right in both the SHR and WKY
rat strains (Table 4 and Table 7, Appendix).

The data confirm and

extend previous results from other laboratories, which showed that
untreated diabetes depressed myocardial ODC activity after 8 days and
4 weeks (14, 25, 69).

However, these earlier studies did not

distinguish between left and right ventricular ODC activity.

The

present results also seem to show that the apparent differences in
ODC activity between left and right ventricles, present in
nondiabetic animals, disappear after imposing chronic, untreated
diabetes.

The difference in workload between left and right

ventricle "is much greater than the incremental increase in workload
imposed on the left ventricle by hypertension (26).

Even acute

elevations in workload can stimulate ODC activity (7).

In general,

the data support the concept that myocardial ODC activity may be
regulated by mechanical and hormonal influences.
Stimulation of myocardial ODC activity by a variety of stimuli
has been shown to precede the development of hypertrophic responses,
and suggests that polyamine synthesis may be an important regulatory
component of cardiac hypertrophy (9, 10, 17, 22, 30, 39, 40, 45, 60,
62).

It is now well established that virtually all stimulatory or

trophic hormones cause an increase in ODC activity in their
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appropriate target tissues (2).

Although, the mechanism of one

regulation has not been well defined, several have been proposed.
First, as mentioned earlier, an increase in one activity in
various tissues may be the result of an increase in the amount of
enzyme protein which, in turn, results from either a decrease in
degradation or an increase in synthesis of the enzyme, or both (61).
This mechanism is supported by an observed accumulation of onc-mRNA
in mouse kidney which had been induced by androgens (31, 64, 68).
Such regulation by alteration in the rate of enzyme protein synthesis
or degradation is unusual in mammalian cells.

Regulation is usually

accomplished by posttranslational modification (47), such as
phosphorylation, thiol modification, and related mechanisms.

In

order for rapid changes to occur by the former mechanism, the protein
must turn over rapidly.

The bulk of the available data indicates

that one has a half-life of approximately 10-20 minutes (40, 65, 67).
Insulin has been shown to increase one activity in various cell
cultures (5).

This increase is due to the formation of new one mRNA

and a subsequent rise in one protein (5).

Mallette and Exton (38)

observed an increase in liver one activity during ex vivo perfusion
with a pharmacological dose of insulin.

Finally, Conover (14) and

Sochor (69) both found that insulin could prevent the decrease in
cardiac one activity due to diabetes.

However, it should be noted

that the insulin-treated animals in these two studies were profoundly
hypoglycemic.

Insulin-induced hypoglycemia can markedly increase

sympathoadrenal activity, which can increase cardiac one activity.
Consequently, the prevention of the diabetic decrease in cardiac one
activity may be a direct or indirect effect of insulin.
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Second, some hormonal influences may affect the affinity of ODC
for its substrate.

Lau and Slotkin proposed that increases in

cardiac ODC due to acute isoproterenol or T treatment resulted in
3
the appearance of a form of the enzyme with an increased affinity for
ornithine (33, 35).

This suggests that the stimulation of cardiac

ODC occurs through a Km shift in the absence of any increase in the
number of ODC molecules.

Millan (41) reported that both the K and
m

V
of ODC were decreased in neonatal rat heart following hypertonic
max
saline injection.

No changes were found in liver and other tissues,

thus supporting the hypothesis that myocardial ODC may be under
unique regulatory control.

However, Flamigni et al. (19) observed a

marked increase in V
, with no change in the K , of myocardial ODC
max
m
from rats treated with isoproterenol.

Thus, the exact role of

changing affinity states as a point of regulation remains unclear.
Third, regulation of the enzyme may involve the expression of
more than one isoform.

Flamigni et al. (18, 19) also showed that two

chromatographically distinct forms of ODC exist in the rat heart.
Separable forms of ODC have been detected in other tissues (56), and
do not seem to differ in their affinity for ornithine (42), but do
differ with respect to their half-lives (49). Both forms are
increased after isoproterenol treatment to the same extent, and thus
the two forms cannot reasonably explain the isoproterenol induction
of ODC (19).

However, the analytical methods used do not eliminate

the possibility of purification artifacts due to the high level of
pyridoxal phosphate used during the extraction (48).

When analysed

by gel electrophoresis, no heterogeneity of ODC protein was observed
with respect to size, but two forms were detected which varied
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slightly in charge (65).

The possible role of ODC isoforms in the

hormonal regulation of the enzyme is not known.
Finally, ODC antizymes may be targets of regulation.

Canellakis

has demonstrated the existence of a non-competitive protein inhibitor
of ODC (antizyme) in various cell types, which is induced by
polyamines (11).

Recent evidence supports the existence of an

antizyme molecule in the rat heart treated with putrescine and
indicates that a significant amount of ODC occurs in an inactive,
complexed form (20).

The absolute and relative levels of ODC

protein, as well as activity, may vary with different conditions or
stimuli.

The antizyme appears to have a half-life comparable to ODC

and thus could constitute a sensitive modulator of enzyme activity
(27).

Also, the decline in ODC protein after exposure to exogenous

polyami~es

has been shown to occur more rapidly than the fall when

protein synthesis is blocked by cycloheximide (11).

This observation

has led to the suggestion that another physiological role of antizyme
may its involvement in the initial step of degradation of the ODC
protein (48), perhaps by making ODC more susceptible to proteolytic
cleavage (27).

The development of specific antibodies and RIA

techniques has permitted more thorough investigation of the mechanism
of rapid ODC induction.

No evidence has been found for the

regulation of ODC enzyme protein by post-translational modifications
or by changes in the content of activating or inhibitory factors.
Seely and Pegg (65, 66) found an excellent correlation between the
amount of ODC protein and the enzymic activity in induced rat liver
and kidney.

ODC activity declines very quickly in cells in response

to exogenous polyamines (11) possibly through the induction of the
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antizyme, and appears to be due to an increased degradation rate and
a decreased rate of synthesis.

However, there is no change in the

content of ODC-mRNA, suggesting that the translation of ODC-mRNA may
be affected by the polyamine content.

In some instances the

increased synthesis of ODC protein in response to acute treatment
with ODC inhibitors is also not accompanied by any change in the mRNA
content (50).

Thus, it seems that overall regulation of ODC protein

occurs both at the level of transcription of the ODC gene and at the
level of translation of the ODC-mRNA.
The presents results, which demonstrated that diabetes caused a
decrease in the maximum velocity without affecting the apparent K of
m
ODC for ornithine (Figure 1 inset, and Table 5), are not inconsistent
with mechanisms 1, 3, and 4 as discussed above.

They do tend to rule

out, however, those which invoke an alteration in the affinity of the
enzyme for its substrate (mechanism 2 above).

This is consistent

with some preliminary results which show a decrease in the total
activity of the enzyme in the cytosol and particulate fraction (Table
8 Appendix). The present results also imply that diabetes causes a
shift in the subcellular localization of the enzyme (Table 8,
Appendix), as indicated by the ratio of ODC activity in the pellet
versus the supernatant fractions.

Obviously, these experiments need

to be repeated in order to obtain a more definitive characterization.
One explanation for this phenomenon may be an increase in the amount
of antizyme-ODC complex.

The ODC antizyme is a non-competitive

protein inhibitor of ODC, which would decrease the velocity of the
decarboxylase reaction, without affecting the K (27).
m
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The design of

our experiments cannot define the role of antizyme in the diabetic
decrease of LV ODC activity.
Experimental diabetes also decreases absorption in the intestinal
tract (8).

Starvation of nondiabetic rats has been shown to depress

ODC activity in normotensive hearts to the same extent as diabetes
does (14).

However, decreased sympathetic activity as well as

a

receptor concentration during fasting could contribute to the
reduction of cardiac ODC activity (79).

Also, serum T and insulin
3

levels are both reduced during fasting and may contribute to the
decrease in cardiac ODC activity (79).

Consequently the overall

influence of malabsorption secondary to diabetes remains unclear.
Another possible explanation of the decrease of LV ODC due to
diabetes may be due to changes in cellular ornithine concentration,
which may have resulted in alterations in the rate of myocardial
synthesis of ODC protein (8).

Ornithine is formed from arginine by

the enzyme arginase, and thus changes in ornithine concentration may
be secondary to alterations in arginine content.

Conceivably, a

fraction of the ornithine substrate might originate from myocardial
arginase in addition to the arginine obtained from the serum.
Ornithine is primarily manufactured in the liver and is an essential
part of the urea cycle.

Ornithine concentration in human plasma

ranges between 30 and 50

µM

(71), which is close to the apparent K
m

of ODC in the left ventricle (Table 5).

It is also known that human

red blood cells contain arginase and can secrete ornithine in
surprisingly high concentrations into the plasma (82).

Finally,

Brosnan et al. (8) showed that ornithine concentration actually
increases in the liver during severe experimental diabetes.
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We

carried out preliminary experiments which demonstrated minimal
arginase activity in the heart (Table 9, Appendix), confirming
previous results (28).

Thus, any role of myocardial arginase in the

effects of diabetes on cardiac ODC activity seems highly unlikely.
Insulin treatment prevented the decrease in LV ODC activity in
diabetic WKY, but did not in the SHR strain (Table 4).

Although

insulin prevented the serum alterations of diabetes in the WKY, it
did not reverse them in the diabetic SHR (Table 1).

However, insulin

restored SAP and HR in the SHR (Table 2) and partially or fully
restored BW, LVW, and RVW (Table 3).

The ineffectiveness of insulin

in diabetic SHR may be due to inappropriate therapy, leading to poor
metabolic control.

These animals were sacrificed 15-20 hours after

their last injection.

Conover et al. (14) and Sochor et al. (69)

both found that insulin could prevent the decrease in cardiac ODC
activity due to diabetes.

However, as mentioned previously, it

should be noted that the insulin-treated animals in these two studies
were profoundly hypoglycemic.

Insulin-induced hypoglycemia can

markedly increase sympathoadrenal activity, which can increase
cardiac ODC activity.

Consequently, the prevention of the diabetic

decrease of cardiac ODC activity in these two studies may be a direct
or indirect effect of insulin.

Hu et al. (29) have described a

temporal increase of liver ODC activity in response to
pharmacological doses of insulin.
any time points after 6 hours.

Unfortunately, they·did not show

Later time points would better reveal

the effectiveness of insulin therapy on tissue OSC activity in
diabetes.

The enzyme's very short half-life may require constant

stimulation in order to maintain normal levels in the myocardium.
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This treatment group is presently being repeated with the aim of
better control of the hyperglycemia in the diabetic SHR.
Induction of ODC activity by different growth factors on various
cultured cells seems to require a minimum concentration of specific
ornithine decarboxylase-inducing amino acids, such as asparagine, in
the medium (57).

Growth factors, including insulin, appear to act

synergistically with the inducing amino acid (57).

Insulin has also

been shown to increase amino acid transport in cultured embryonic
chick heart cells (63).

Thus, the inability of insulin to restore LV

ODC activity in diabetic SHR may also have been related, in part, to
decreased plasma or tissue concentrations of specific ODC-inducing
amino acids during diabetes.
T treatment of diabetic SHR and WKY restored serum T levels
3
3
(Table 1) and partially prevented the decline in LV ODC activity
(Table 4).

It also prevented the depressions in HR and SAP of SHR

(Table 2).

Hypothyroidism, which is associated with diabetes (53),

has been shown to decrease cardiac ODC activity (13), whereas
injections of T stimulate it (12, 13, 34, 45, 46, 54).
3

Raymondjean

et al. (54) found that T induced a biphasic response of cardiac ODC
3
activity, with peaks at 4 and 21 hours that were inhibited by
cycloheximide, indicating that T increased the synthesis of new ODC
3
molecules.

The trough of this response could be explained by the

complexing of ODC to antizyme, since there was an accumulation of ODC
molecules that " ... were catalytically inactive but inununologically
reactive ... " (54).
In sununary, the results of this study show that chronic,
untreated diabetes depresses ODC activity in the left ventricle, but
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not the right ventricle, of the rat heart.
is:

This effect of diabetes

1) Not influenced by preexisting left ventricular hypertrophy in

the SHR model of hypertension; 2)

Reversible by insulin treatment

which confers good metabolic control; 3) Partially reversible by T
3
treatment; and 4)

Not associated with any apparent change in the

affinity of the enzyme for its substrate.

The results support the

hypothesis that both insulin and thyroid hormone, along with
mechanical stress on the ventricle, are important regulators of
myocardial ODC activity.

They also suggest that neither ODC activity

nor its possible regulation by these factors is uniquely influenced
by established left ventricular hypertrophy.
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APPENDIX.

RESULTS ANCILLARY TO MANUSCRIPT
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Figure 2a,b. Myocardial Ornithine Decarboxylase activity is
typically higher in weanlings than in mature adult. Thus,
characterization of the enzyme was initially carried out in 21 to 35
day old Sprague Dawley (SD) rat hearts. Figure 3a depicts the
Michaelis-Menten kinetics of myocardif! ODC activity over 2 hours,
obtained by isotopically diluting (1- C) L-ornithine with unlabelled
L-ornithine to the desired concentration. The double reciprocal plot
of weanling SD cardiac ODC f~tivity is shown in Figure 3b. The K is
35 uM and v
is 710 pmol
co2 generated/hr/mg protein, obtaine~ by
linear regr~~ion analysis.
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TABLE 6.

Left ventricular ornithine decarboxylase (ODC) in nondiabetic,
diabetic and treated SHR, ~KY and SD.
Left Veniricular ODC Activity
(pmol ~co /hr/mg protein)

2

Strain
Group

STUDY l

(Ornithine]

n

400 µM

STUDY 2

n

200 µM
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n
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TABLE 7.

Right Ventricular ODC activity in nondiabetic, diabetic and treated
SHR, h~Y and SD rats.

Strain
Group

prnol

n

l' RV ODC Activity
~co generated/hr/mg protein

2

SHR
Nondiabetic

9

~o

+ 25

Diabetic

8

29

+ 23

Diabetic + T3

6

46

+ 26

Diabetic + I

8

32

:!:

Nondiabetic + T3

7

30

:!: 15
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:!: 18
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8
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TABLE 8.

Subcellular localization of ODC activity in nondiabetic and diabetic
SHR and 1.l<Y.

--------------------------------- ------ --------------------------------------Strain
Group

Pellet

Supernatant

Total

n

Pellet
Supernatant

SHR
Nondiabetic

2

12 l

66

187

l. 83

Diabetic

2

82

21

103

3.91

Nondiabetic

2

65

57

122

l. 14

Diabetic

2

84

36

120

2. 33

1-"KY

Values are rneans of ODC activity from Supernatant of 5% homogenate as described
previ o usly in Met~~ds er frorn reconstitution of Pellet with 25 ~1 HEPES.
ODC units; pmol ~co generated / hr / mg protein, using 25 uM Ornithine.

2
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TABLE 9.

Tissue

Arginase activity in liver and heart of adult male Sprague Dawley
rats.

n

Arginase activity

Liver

255 + 48

Fresh
Frozen

·~

281 + 31

Heart
Fresh

5

0.25 + D.05

.f rozen

5

0.21 + 0.08

Values are qeans ±SD fer Argin.ise ."ictivity deter1:1ined by the detection of ure.1
generation.
Arginase units: ·~oles of urea for1:1ed/1:1in/g tissue weight
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